All In Biotech

Drug Trial Radar · NCT07167758

A Study Evaluating TRIV-509 in Atopic Dermatitis

A Phase 2a, Randomized, Multicenter, Double-Blind, Placebo- Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Multiple Subcutaneous Doses of TRIV-509 in Adults With Moderate to Severe Atopic Dermatitis

Last checked: Nov 20, 2026Latest source record: Apr 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

95

Actual

Start

Aug 26, 2025

Primary completion

Oct 2026

Study completion Jun 2027

Sponsor

Lead sponsor
Triveni BioIndustry
Sponsor type
Industry
First posted
Sep 11, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this interventional study is to learn if TRIV-509 works to treat moderate to severe atopic dermatitis in adults. It will also evaluate the safety of TRIV-509. Participants will receive 4 doses of the study intervention that they are randomized to (TRIV-509 or placebo), and at Week 16 will cross over and receive 4 doses of the other study intervention. The study duration for individual participants is up to 57 weeks, including a Screening period of up to 30 days.

Conditions

  • Atopic Dermatitis

Interventions

  • TRIV-509Drug

    TRIV-509 (Subcutaneous injection)

  • PlaceboDrug

    Drug: Placebo (Matching Placebo subcutaneous injection)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of participants with improvement of AD at Week 16Time frame: Baseline to Week 16

Locations

32 sites in 7 countries. Site status is shown where the registry gives one.

  • Triveni Bio Site #11

    Fountain Valley, California

  • Triveni Bio Site #4

    San Diego, California

  • Triveni Bio Site #3

    Miami, Florida

  • Triveni Bio Site #6

    Indianapolis, Indiana

  • Triveni Bio Site #10

    South Bend, Indiana

  • Triveni Bio Site #1

    Camp Hill, Pennsylvania

  • Triveni Bio Site #16

    Bellaire, Texas

  • Triveni Bio Site #5

    Dallas, Texas

  • Triveni Bio Site #8

    Spokane, Washington

  • Triveni Bio Site #38

    Pleven, Bulgaria

  • Triveni Bio Site #39

    Sofia, Bulgaria

  • Triveni Bio Site #13

    Ajax, Ontario, Canada

  • Triveni Bio Site #17

    Newmarket, Ontario, Canada

  • Triveni Bio Site #12

    Niagara Falls, Ontario, Canada

  • Triveni Bio Site #15

    North York, Ontario, Canada

  • Triveni Bio Site #22

    Ostrava, Czechia

  • Triveni Bio Site #31

    Pardubice, Czechia

  • Triveni Bio Site #21

    Prague, Czechia

  • Triveni Bio Site #37

    Prague, Czechia

  • Triveni Bio Site #23

    Prague, Czechia

  • Triveni Bio Site #41

    Budapest, Hungary

  • Triveni Bio Site #34

    Budapest, Hungary

  • Triveni Bio Site #43

    Debrecen, Hungary

  • Triveni Bio Site #29

    Sosnowiec, Poland

  • Triveni Bio Site #33

    Wroclaw, Lower Silesian Voivodeship, Poland

  • Triveni Bio Site #28

    Warsaw, Masovian Voivodeship, Poland

  • Triveni Bio Site #24

    Chorzów, Silesian Voivodeship, Poland

  • Triveni Bio Site #25

    Katowice, Silesian Voivodeship, Poland

  • Triveni Bio Site #27

    Katowice, Silesian Voivodeship, Poland

  • Triveni Bio Site #30

    Poznan, Wielkopolska, Poland

  • Triveni Bio Site #26

    Poznan, Wielkopolska, Poland

  • Triveni Bio Site #18

    Kyiv, Ukraine

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.